Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked vigilantly but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past several shares. The 1st CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set away what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire job interview that I came away with a poor viewpoint of the company.

Irony of irony, my poor opinion of the company has grown steadily, though the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the technology and connected intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) along with the very first brand new drug application approval ($5 million), and also royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it’s this individual treatment in addition to a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple presentations in addition to multiple publications.

Can all this be smoke cigarettes and mirrors? That is a question I have been asking myself through the really beginning of the interest of mine in this particular organization. Judging by way of the multiples of a huge number of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a classic battleground, or even some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *